HIV VACCINE development

 

 

 

InnaVirVax and piCHEM agree cooperation on the development of a synthetic therapeutic vaccine candidate for HIV-infection.

 

 

InnaVirVax SA (www.innavirvax.fr), a privately-owned biopharmaceutical company located in the Paris Region biopark of Evry, France is dedicated to the development of a cutting edge discovery in the field of therapy/prevention and prognosis of AIDS and HIV infection and new cancer therapies.

 

piCHEM provides its extensive know-how in the development and production of peptide based active pharmaceutical ingredients for the development of new and innovative drugs.

The agreed cooperation is another important step for piCHEM to broaden its competency in the development and production of vaccines.

piCHEM is very proud to be involved in the fight against HIV/AIDS!